Inflammatory bowel disease: review and future view

Maher, Maha M

doi:10.2741/485

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammatory bowel diseases (IBD) represent a spectrum of disorders characterized by chronic gut inflammation in individuals with genetic and/or environmental risk factors [1, 2]. At one end of the clinical spectrum in IBD is Crohn’s disease (CD), defined by discontinuous, transmural, frequently granulomatous intestinal inflammation, which can involve the small and/or large bowel [3, 4].…”

Section: Introductionmentioning

confidence: 99%

Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn’s Disease and Ulcerative Colitis

et al. 2015

View full text Add to dashboard Cite

Background Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by chronic intestinal inflammation due to immunological, microbial and environmental factors in genetically predisposed individuals. Advances in the diagnosis, prognosis and treatment of IBD require the identification of robust biomarkers that can be used for molecular classification of diverse disease presentations. We previously identified five genes, RELA, TNFAIP3 (A20), PIGR, TNF and IL8, whose mRNA levels in colonic mucosal biopsies could be used in a multivariate analysis to classify patients with Crohn’s disease (CD) based on disease behavior and responses to therapy. Aim We compared expression of these 5 biomarkers in IBD patients classified as having CD or ulcerative colitis (UC), and in healthy controls. Results Patients with CD were characterized as having decreased median expression of TNFAIP3, PIGR and TNF in non-inflamed colonic mucosa as compared to healthy controls. By contrast, UC patients exhibited decreased expression of PIGR and elevated expression of IL8 in colonic mucosa compared to healthy controls. A multivariate analysis combining mRNA levels for all 5 genes resulted in segregation of individuals based on disease presentation (CD vs. UC) as well as severity, i.e., patients in remission vs. those with acute colitis at the time of biopsy. Conclusion We propose that this approach could be used as a model for molecular classification of IBD patients, which could further be enhanced by the inclusion of additional genes that are identified by functional studies, global gene expression analyses, and genome-wide association studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn’s Disease and Ulcerative Colitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Some nutritional and natural components have been studied for their effectiveness in treating IBD by controlling production of proinflammatory cytokines [4][5][6][7][8][9]. Furthermore, microorganisms such as fungi and bacteria produce many metabolites that have been developed into drugs.…”

Section: Introductionmentioning

confidence: 99%

Amelioration of dextran sodium sulfate-induced colitis in mice by Rhodobacter sphaeroides extract

2014

View full text Add to dashboard Cite

Bacteria can produce some compounds in response to their environment. These compounds are widely used in cosmetic and pharmaceutical applications. Some probiotics have immunomodulatory activities and modulate the symptoms of several diseases. Autoimmune diseases represent a complex group of conditions that are thought to be mediated through the development of autoreactive immunoresponses. Inflammatory bowel disease (IBD) is common autoimmune disease that affects many individuals worldwide. Previously, we found that the extracts of Rhodobacter sphaeroides (Lycogen) inhibited nitric oxide production and inducible nitric-oxide synthase expression in activated macrophages. In this study, the effect of Lycogen™, a potent anti-inflammatory agent, was evaluated in mice with dextran sodium sulfate (DSS)-induced colitis. Oral administration of Lycogen™ reduced the expressions of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) in female BABL/c mice. In addition, the increased number of bacterial flora in the colon induced by DSS was amelirated by Lycogen™. The histological score of intestinal inflammation in 5% DSS-treated mice after oral administration of Lycogen™ was lower than that of control mice. Meanwhile, Lycogen™ dramatically prolonged the survival OPEN ACCESSMolecules 2012, 17 13623 of mice with severe colitis. These findings identified that Lycogen™ is an anti-inflammatory agent with the capacity to ameliorate DSS-induced colitis.

show abstract

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Yönal

Eren²,

Yılmaz³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: The endocannabinoid system can exert beneficial effects on gastrointestinal inflammation, and cannabinoid receptor-2 (CB2) agonists may represent a new therapeutic approach in inflammatory bowel disease (IBD). A functional CB2 Q63R polymorphism (rs35761398) in the CNR2 gene has been shown to affect the immunomodulating properties of the CB2 receptor. We sought to investigate whether the functional CB2 Q63R polymorphism (rs35761398) is associated with IBD susceptibility in a Turkish clinical sample. Materials and Methods: A total of 202 IBD patients, comprising 101 Crohn's disease (CD) patients and 101 ulcerative colitis (UC) patients, and 101 healthy controls were included in the study. The CB2 Q63R polymorphism was genotyped using real-time PCR. Results: There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for CD relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for UC relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either CD (p= 0.71) or UC patients (p=0.59). Conclusion: These pilot findings suggest that CB2 Q63R polymorphism does not play a major role in genetic susceptibility to IBD or in its disease phenotypes among Turkish subjects.

show abstract

Inflammatory bowel disease: review and future view

Cited by 3 publications

References 28 publications

Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn’s Disease and Ulcerative Colitis

Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn’s Disease and Ulcerative Colitis

Amelioration of dextran sodium sulfate-induced colitis in mice by Rhodobacter sphaeroides extract

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Contact Info

Product

Resources

About